Daxor Targets Dysautonomia Market with First Conference Exhibition
Event summary
- Daxor Corporation will exhibit at the 14th Annual Dysautonomia International Conference from July 9–12, 2026.
- The company will showcase its FDA-cleared Blood Volume Analyzer (BVA) for objective plasma and red blood cell data in dysautonomia therapy.
- Daxor aims to shift autonomic medicine from subjective symptom tracking to precision data-driven diagnostics.
- John L. Jefferies, MD, MPH, MBA, Daxor's Chief Medical Officer, highlights BVA's role in replacing clinical guesswork with accurate baselines for treatment.
The big picture
Daxor's exhibition at the Dysautonomia International Conference marks a strategic pivot toward precision diagnostics for autonomic disorders. The move aligns with broader industry trends favoring objective, data-driven healthcare solutions, particularly in complex conditions like dysautonomia where traditional diagnostics often fall short. With its FDA-cleared BVA technology, Daxor aims to carve out a niche in a market increasingly valuing individualized treatment approaches.
What we're watching
- Market Expansion
- How Daxor's entry into the dysautonomia space will affect its market penetration and revenue growth.
- Physician Adoption
- Whether clinicians will increasingly adopt BVA for data-driven therapeutic decisions in autonomic disorders.
- Competitive Positioning
- The pace at which Daxor can differentiate itself from traditional diagnostic methods in high-cost medical conditions.
Related topics